

BAB VI

DAFTAR PUSTAKA

- Alaggio, R., Amador, C., Anagnostopoulos, I., Attygalle, A.D., Araujo, I.B. de O., Berti, E., Bhagat, G., Borges, A.M., Boyer, D., Calaminici, M., Chadburn, A., Chan, J.K.C., Cheuk, W., Chng, W.-J., Choi, J.K., Chuang, S.-S., Coupland, S.E., Czader, M., Dave, S.S. and de Jong, D. (2022). The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. *Leukemia*, 36(7), pp.1720–1748. doi:10.1038/s41375-022-01620-2.
- Broyde, A., Boycov, O., Strenov, Y., Okon, E., Shpilberg, O. and Bairey, O. (2009). Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma. *American Journal of Hematology*, 84(6), pp.338–343. doi:10.1002/ajh.21406.
- CDC (2019). *Lymphoma*. [online] Centers for Disease Control and Prevention. Available at: <https://www.cdc.gov/cancer/lymphoma/index.htm>.
- Daphne de Jong, Xie, W., Rosenwald, A., Mukesh Chhanabhai, Philippe Gaulard, Klapper, W., Lee, A., Sander, B., Thorns, C., Campo E., Thierry Jo Molina, Hagenbeek, A., Horning, S.J., Lister, A., Raemaekers, J., Salles, G., Gascoyne, R.D. and Weller, E. (2008). Retracted: Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). *Journal of Clinical Pathology*, 62(2), pp.128–138. doi:<https://doi.org/10.1136/jcp.2008.057257>.
- Dewi, Y.A., Permana, A.D., Nazar, I.B. and Hernowo, B.S. (2022). Survival Rate of Patients with Diffuse Large B-Cell Lymphoma in the Head and Neck. In *2nd Global Health and Innovation in conjunction with 6th ORL Head and Neck Oncology Conference (ORLHN 2021)* (pp. 71-77). Atlantis Press.
- Dharma, K.K. (2011). *Metodologi Penelitian Keperawatan*. Jakarta : Trans Info Media
- Haroon, S., Hashmi, A.A., Khurshid, A., Kanpurwala, M.A., Mujtuba, S., Malik, B. and Faridi, N. (2013). Ki67 Index in Breast Cancer: Correlation with Other Prognostic Markers and Potential in Pakistani Patients. *Asian Pacific Journal of Cancer Prevention*, 14(7), pp.4353–4358. doi:<https://doi.org/10.7314/apjcp.2013.14.7.4353>.

- Hashmi, A.A., Iftikhar, S.N., Nargus, G., Ahmed, O., Asghar, I.A., Shirazi, U.A., Afzal, A., Irfan, M. and Ali, J. (2021). Ki67 Proliferation Index in Germinal and Non-Germinal Subtypes of Diffuse Large B-Cell Lymphoma. *Cureus*. doi:10.7759/cureus.13120.
- He, X., Chen, Z., Fu, T., Jin, X., Yu, T., Liang, Y., Zhao, X. and Huang, L. (2014). Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis. *BMC Cancer*, [online] 14, p.153. doi:10.1186/1471-2407-14-153.
- Huber, F., Zwickl-Traxler, E., Pecherstorfer, M. and Singer, J. (2021). Evaluation of Ki-67 as a Prognostic Marker in Diffuse Large B-Cell Lymphoma—A Single-Center Retrospective Cohort Study. *Current Oncology*, [online] 28(6), pp.4521–4529. doi:10.3390/curroncol28060383
- Istiadi, H., Sadhana, U., Puspasari, D., Miranti, I.P., Karlowee, V., Listiana, D.E. and Prasetyo, A. (2021). Prognostic significance of double expressor lymphoma subtype in patient with diffuse large B-cell lymphoma. *Bali Medical Journal*, 10(1), p.366. doi:10.15562/bmj.v10i1.2188.
- Jamil, A. and Mukkamalla, S.K.R. (2020). *Lymphoma*. [online] PubMed. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK560826/>.
- Kanas, G., Ge, W., Quek, R.G.W., Keeven, K., Nersesyan, K. and Jon E. Arnason (2021). Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020–2025. *Leukemia & Lymphoma*, 63(1), pp.54–63. doi:10.1080/10428194.2021.1975188.
- Lymphoma Australia. (n.d.). *Diffuse Large B cell (DLBCL)*. [online] Available at: <https://www.lymphoma.org.au/types-of-lymphoma/non-hodgkin-lymphoma/aggressive-fast-growing-b-cell-nhl/diffuse-large-b-cell-dlbcl/>.
- Miao, Y., Medeiros, L.J., Li, J. and Young, K.H. (2018). Diffuse large B-cell lymphoma with molecular variations more than ABC and GCB classification. *Precision Cancer Medicine*, 1, pp.4–4. doi:10.21037/pcm.2018.06.03.
- Mudassar, M., Hameed, S., Aslam, S., Majeed, R., Khan, R. ullah and Majeed, M. (2019). Ki-67 Proliferative Index in The Non-Hodgkin’s Lymphoma and Its Clinical Significance. *Annals of Punjab Medical College (APMC)*, [online] 13(2), pp.108–112. doi:10.29054/apmc/2019.64.
- Padala, S.A. and Kallam, A. (2020). *Cancer, Diffuse Large B Cell Lymphoma*. [online] PubMed. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK557796/>.

- Polit, D. & Beck, C. (2012). *Nursing research: Generating and assessing evidence for nursing practice*. 9th ed. Philadelphia, PA: Lippincott, Williams, Wilkins.
- Putri, S., Setiawan, E., Saldi, S.R.F., Khoe, L.C., Sari, E.R., Megraini, A., Nadjib, M., Sastroasmoro, S. and Armansyah, A. (2022). Adding rituximab to chemotherapy for diffuse large B-cell lymphoma patients in Indonesia: a cost utility and budget impact analysis. *BMC health services research*, [online] 22(1), p.553. doi:10.1186/s12913-022-07956-w.
- Roschewski, M., Phelan, J.D. and Wilson, W.H. (2020). Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma. *The Cancer Journal*, 26(3), pp.195–205. doi:10.1097/ppo.0000000000000450.
- Ruppert, A.S., Dixon, J.G., Salles, G.A., Wall, A., Cunningham, D., Poeschel, V., Haioun, C., Tilly, H., Ghesquieres, H., Ziepert, M., Flament, J., Flowers, C., Shi, Q. and Schmitz, N. (2020). International prognostic indices in diffuse large B-cell lymphoma (DLBCL): a comparison of IPI, R-IPI and NCCN-IPI. *Blood*. doi:10.1182/blood.2019002729.
- Sapkota, S. and Shaikh, H. (2020). *Non-Hodgkin Lymphoma*. [online] PubMed. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK559328/>.
- SEER. (2018). *Diffuse Large B-Cell Lymphoma - Cancer Stat Facts*. [online] Available at: <https://seer.cancer.gov/statfacts/html/dlbcl.html>.
- Shi, X., Liu, X., Li, X., Li, Y., Lu, D., Sun, X., Li, Y., Hu, S., Zhang, Y., Zhou, X., Wang, X., Chen, H. and Fang, X. (2021). Risk Stratification for Diffuse Large B-Cell Lymphoma by Integrating Interim Evaluation and International Prognostic Index: A Multicenter Retrospective Study. *Frontiers in Oncology*, 11. doi:10.3389/fonc.2021.754964.\
- Swerdlow, S.H. (2017). *WHO classification of tumours of haematopoietic and lymphoid tissues*. [online] Lyon: International Agency For Research On Cancer. Available at: <http://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/Who-Classification-Of-Tumours-Of-Haematopoietic-And-Lymphoid-Tissues-2017> [Accessed 30 Apr. 2019].
- Tang, Y.-L., Zhou, Y., Cheng, L.-L., Su, Y.-Z. and Wang, C.-B. (2017). BCL2/Ki-67 index predict survival in germinal center B-cell-like diffuse large B-cell lymphoma. *Oncology Letters*, [online] 14(3), pp.3767–3773. doi:10.3892/ol.2017.6577.
- Zaiem, F., Jerbi, R., Albanyan, O., Puccio, J., Kafri, Z., Yang, J. and Gabali, A.M. (2020). High Ki67 proliferation index but not cell-of-origin subtypes is

associated with shorter overall survival in diffuse large B-cell lymphoma. *Avicenna Journal of Medicine*, [online] 10(4), pp.241–248. doi:10.4103/ajm.ajm_81_20.

Zhou, Z., Sehn, L.H., Rademaker, A.W., Gordon, L.I., Lacasce, A.S., Crosby-Thompson, A., Vanderplas, A., Zelenetz, A.D., Abel, G.A., Rodriguez, M.A., Nademanee, A., Kaminski, M.S., Czuczman, M.S., Millenson, M., Niland, J., Gascoyne, R.D., Connors, J.M., Friedberg, J.W. and Winter, J.N. (2014). An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. *Blood*, [online] 123(6), pp.837–842. doi:10.1182/blood-2013-09-524108.

Zaiem, F., Jerbi, R., Albanyan, O., Puccio, J., Kafri, Z., Yang, J. and Gabali, A.M. (2020). High Ki67 proliferation index but not cell-of-origin subtypes is associated with shorter overall survival in diffuse large B-cell lymphoma. *Avicenna Journal of Medicine*, [online] 10(4), pp.241–248. doi:https://doi.org/10.4103/ajm.ajm_81_20.